ArticleThe open ophthalmology journal2014
Ocular surface alterations and topical antiglaucomatous therapy: a review.
Article in The open ophthalmology journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Comparative safety and efficacy of brinzolamide/timolol and dorzolamide/timolol in the treatment of glaucoma patients: A systematic review and meta-analysis.European journal of ophthalmology · 2026Pooled it
- The Effects of Intraocular Pressure-Lowering Drops on the Tear Film Assessed by a Novel High-Resolution Tear Film Imager.Diagnostics (Basel, Switzerland) · 2026Article
- A liposomal formulation of cyclosporine a shows promising results in treating symptoms of moderate to severe dry eye disease in dogs.Drug delivery and translational research · 2026Article
- Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma.Drug delivery · 2025Article
- The effect of treatment of primary congenital glaucoma on meibomian glands and tear film.Eye (London, England) · 2025Article
- Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents.Drug delivery and translational research · 2024Article
- A Preservative-Free Approach - Effects on Dry Eye Signs and Symptoms After Cataract Surgery.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications.Ophthalmology and therapy · 2022Review
- Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment.Pharmaceutics · 2022Article
- Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Ocular benzalkonium chloride exposure: problems and solutions.Eye (London, England) · 2022Review
- Effects of Glaucoma Medication on Dry Eye Syndrome and Quality of Life in Patients with Glaucoma.Korean journal of ophthalmology : KJO · 2021Article
- Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops.Journal of clinical medicine · 2020Article
- Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma.Indian journal of ophthalmology · 2019Article
- Article
- Ocular Surface Disease and Glaucoma Medications: A Clinical Approach.Eye & contact lens · 2019Review
- The use of preservatives in dry eye drops.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens.Ophthalmology and therapy · 2018Article
- Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice.Scientific reports · 2018Article
- Glaucoma therapy: preservative-free for all?Clinical ophthalmology (Auckland, N.Z.) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular Surface Disease (OSD) is prevalent among medically treated patients with glaucoma. This is basically related to three key-points: OSD and glaucoma are both prevalent in elderly and are common comorbidities in the same patient; the role of the active ingredient of the medical antiglaucomatous therapy; the role of the preservative agent of this medical therapy. Considering the actual state of literature we can state that the active glaucoma agent have a role in OSD, but the main cause seems to be the preservative agent, in particular referring to benzalkonium chloride, BAK. In the clinical evaluation of dry eye patients there is no actually established gold standard. Since the ocular surface injury not only causes dry eye, red eye, eye itching, photophobia and other discomforts, but also increases the risk of failure of glaucoma surgery in patients, it becomes fundamental a complete and good clinical evaluation of OSD (considering Schirmer's test, tear breakup time, corneal and conjunctival staining) together with a good evaluation of patients' quality of life (with validated questionnaires). Development of complex preparations, preservative-free and/or novel preservative preparations for glaucoma therapy could provide a promising approach in the prevention of ocular surface injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.